ABVC

ABVC BIOPHARMA, INC.

Nasdaq, OTC · CIK 1173313

Last close1.01
Daily change-0.01 (-0.98%)
10 Years gain-99.72%
Dividends TTM0
Dividend yield0.00%

Fundamental Analysis

ABVC · STANDARD

SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231

Screener
Fundamental
58.9
Momentum
100.0
Acceleration
100.0
Confidence
83.0
Annual Revenue13
Quarterly Revenue44
Annual CFO17
Balance SheetAvailable
RankingEligible

Score Breakdown

Growth17.7 / 25
Quality19.7 / 25
Capital Efficiency11.1 / 20
Balance Sheet2.4 / 15
Shareholder Economics5.7 / 10
Forward Indicators2.3 / 5

Signals

Gross margin expansionGross margin improved by 954.4161 percentage points.
Operating leverageOperating margin improved by 30060.7333 percentage points.
ROIC expansionROIC improved by 278.8022 percentage points.
Net debt reductionNet debt declined versus the comparison period.

Warnings

Heavy share dilution · HIGHDiluted share count increased 138.8684%.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.

Key Metrics

Revenue Growth TTM5,042.66%OK
Revenue CAGR 3Y12.72%OK
Gross Margin99.96%OK
Operating Margin-293.74%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-40.18%OK
Incremental Operating Margin 3Y1,082.66%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y138.87%OK
SBC / Revenue143.99%OK
SBC / FCFn/aNOT_MEANINGFUL

Financial History

PeriodRevenueGross ProfitOperating IncomeCFOFCFGross MarginOp MarginFCF MarginROICShares
2025 FY Dec 31, 2025n/a$0.00-$7.15M-$2.99Mn/an/an/an/a-87.76%20.11M
2025 FY Dec 31, 2024$509,589.00$508,826.00-$4.71M-$1.81Mn/a99.85%-923.34%n/a-182.79%11.67M
2024 FY Dec 31, 2023$152,430.00-$149,607.00-$6.77M-$4.19M-$4.21M-98.15%-4,439.24%-2,760.64%-149.63%4.34M
2023 FY Dec 31, 2022$969,783.00$683,368.00-$15.11M-$7.40M-$7.52M70.47%-1,558.54%-775.23%-254.64%3.17M
2022 FY Dec 31, 2021$355,797.00$350,711.00-$11.71M-$7.60M-$7.62M98.57%-3,290.07%-2,140.33%-346.29%25.05M

Formula Trace

MetricValueFormulaStatusSource
Revenue TTM$1.30Msum latest 4 fiscal quarters RevenueOK0001213900-25-075644, 0001213900-26-023062
Revenue Growth TTM5,042.66%Revenue_TTM / Revenue_TTM_1Y_ago - 1OK0001213900-25-075644, 0001213900-26-023062
Revenue CAGR 3Y12.72%(Revenue_current / Revenue_3Y_ago)^(1/3) - 1OK0001213900-26-023063
Revenue CAGR 5Y-6.2%(Revenue_current / Revenue_5Y_ago)^(1/5) - 1OK0001213900-26-023063
Gross Profit CAGR 3Y13.21%(GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1OK0001213900-26-023063
Operating Income Growthn/aOperatingIncome_current / OperatingIncome_prior_year - 1INSUFFICIENT_HISTORY0001213900-25-075644, 0001213900-26-023062
FCF Growthn/aFCF_current / FCF_prior_year - 1INSUFFICIENT_HISTORYderived
Revenue Growth Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Gross Profit Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Operating Income Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
FCF Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Gross Margin99.96%Gross Profit / RevenueOK0001213900-25-075644, 0001213900-26-023062
Operating Margin-293.74%Operating Income / RevenueOK0001213900-25-075644, 0001213900-26-023062
ROIC-40.18%NOPAT / Average Invested CapitalOK0001213900-25-075644, 0001213900-26-023062
Net Debt / CFOn/aNet Debt / CFONOT_MEANINGFUL0001213900-26-023062
Current Ratio0.51xCurrent Assets / Current LiabilitiesOKderived
Cash / Debt0.32x(Cash + Short-term Investments) / Total DebtOK0001213900-26-023062
SBC / Revenue143.99%SBC / RevenueOK0001213900-25-075644, 0001213900-26-023062